受体酪氨酸激酶抑制剂在恶性胶质瘤中的临床试验进展
Journal of International Oncology（2013）
Abstract
恶性胶质瘤的发生发展与受体酪氨酸激酶(RTK)过表达及其信号转导通路的异常激活密切相关,据此开发出的靶向治疗药物如RTK抑制剂、RTK下游信号通路抑制剂和多靶点抑制剂等能在分子水平上对恶性胶质瘤进行靶向性治疗,其中部分已通过临床试验,并取得良好疗效.
MoreTranslated text
Key words
Glioma,Clinical trial,Receptor protein-tyrosine kinase inhabitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined